Posted by Michael Wonder on 28 Sep 2020
Opdivo and Yervoy combination therapy approved in Japan to expand use for the treatment of microsatellite instability high colorectal cancer, and Opdivo for additional dosage and administration in monotherapy dosing regimen
25 September 2020 - Ono Pharmaceutical and Bristol-Myers Squibb announced today that the companies have received approval for combination therapy of Opdivo (nivolumab) intravenous infusion and Yervoy (ipilimumab) injection in Japan to expand the combination use for the treatment of microsatellite instability high unresectable advanced or recurrent colorectal cancer that has progressed following chemotherapy, for a partial change in approved items of the manufacturing and marketing approval.
In addition, ONO announced that it has also received approval of Opdivo for additional dosage and administration to intravenously infuse at “480 mg (over 30 minutes) every 4 weeks” in the monotherapy dosing regimen, for a partial change in approved items of the manufacturing and marketing approval.
